ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37581981

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.

Sierra J and 14 others. Blood Adv, 2023. Cited by 19 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. Papers, record 37581981. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37581981

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
PubMed
Journal
Blood Adv
PubMed
Year
2023
PubMed
Publication types
Clinical Trial, Phase III, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
1.87
iCite
Revised in PubMed
2026-01-27
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sierra JJorgehttps://orcid.org/0000-0002-7966-0356
2Montesinos PPauhttps://orcid.org/0000-0002-3275-5593
3Thomas XXavier
4Griskevicius LLaimonas
5Cluzeau TThomas
6Caillot DDenis
7Legrand OOllivier
8Minotti CClara
9Luppi MMario
10Farkas FFiras

1 to 10 of 15Source PubMed

See all 15 authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DaunorubicinMajor topic
Leukemia, Myeloid, AcuteMajor topic
Male
Female
Humans
Aged
Middle Aged
Idarubicin
Staurosporine
Antibiotics, Antineoplastic
Anthracyclines
fms-Like Tyrosine Kinase 3

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03379727
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Derived from the trialYes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130,466,752Is there a standard of care for relapsed AML?Best Pract Res Clin Haematol2018https://conductscience.org/library/papers/30466752PubMed
212,124,173Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.Cancer Cell2002https://conductscience.org/library/papers/12124173PubMed
330,563,875Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.Blood2019https://conductscience.org/library/papers/30563875PubMed
431,902,138The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia.Cancer Med2020https://conductscience.org/library/papers/31902138PubMed
535,658,497Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.Am Soc Clin Oncol Educ Book2022https://conductscience.org/library/papers/35658497PubMed
615,339,685Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.Haematologica2004https://conductscience.org/library/papers/15339685PubMed
728,774,275The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study.BMC Public Health2017https://conductscience.org/library/papers/28774275PubMed
828,644,114Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.N Engl J Med2017https://conductscience.org/library/papers/28644114PubMed
930,651,634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
1010,888,033PKC412--a protein kinase inhibitor with a broad therapeutic potential.Anticancer Drug Des2000https://conductscience.org/library/papers/10888033PubMed

1 to 10 of 27

See all 27 references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42,981,093Overall Survival in Adults With Acute Myeloid Leukemia Initiating Quizartinib vs Midostaurin With Chemotherapy.JAMA Netw Open2026https://conductscience.org/library/papers/42981093PubMed
42,671,173Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.Am J Hematol2026https://conductscience.org/library/papers/42671173PubMed
42,452,347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347PubMed
42,337,231Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.Blood Cancer J2026https://conductscience.org/library/papers/42337231PubMed
42,065,041AI-Guided Discovery of Oncogenic Signaling Crosstalk in Tumor Progression and Drug Resistance.Oncol Res2026https://conductscience.org/library/papers/42065041PubMed
41,827,706A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.Cancers (Basel)2026https://conductscience.org/library/papers/41827706PubMed
41,749,868Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach.Cancers (Basel)2026https://conductscience.org/library/papers/41749868PubMed
41,671,383Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.Am J Hematol2026https://conductscience.org/library/papers/41671383PubMed
41,150,745Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41150745PubMed
40,990,091Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.Am J Hematol2025https://conductscience.org/library/papers/40990091PubMed

1 to 10 of 14

See all 14 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CYP3A41,576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
FLT32,322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
NPM14,869PubTator's text mininghttps://conductscience.org/library/genes/4869NCBI Gene

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
MIDOSTAURINCHEMBL608533Derived from the trial1https://conductscience.org/library/drugs/CHEMBL608533ChEMBL
CYTARABINECHEMBL803Derived from the trial1https://conductscience.org/library/drugs/CHEMBL803ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37581981

GET https://conductscience.org/api/papers/v1/37581981/references?page=2

API referenceFor AI assistants